nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimozide—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0802	0.1	CbGbCtD
Pimozide—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0689	0.0861	CbGbCtD
Pimozide—CYP3A7—Dexamethasone—ankylosing spondylitis	0.0534	0.0667	CbGbCtD
Pimozide—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.0534	0.0667	CbGbCtD
Pimozide—CYP2C19—Prednisone—ankylosing spondylitis	0.0517	0.0646	CbGbCtD
Pimozide—CYP2E1—Dexamethasone—ankylosing spondylitis	0.0515	0.0644	CbGbCtD
Pimozide—ABCB1—Betamethasone—ankylosing spondylitis	0.0448	0.056	CbGbCtD
Pimozide—ABCB1—Prednisolone—ankylosing spondylitis	0.0442	0.0552	CbGbCtD
Pimozide—ABCB1—Prednisone—ankylosing spondylitis	0.0417	0.0522	CbGbCtD
Pimozide—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0413	0.0516	CbGbCtD
Pimozide—CYP3A5—Dexamethasone—ankylosing spondylitis	0.04	0.05	CbGbCtD
Pimozide—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0323	0.0404	CbGbCtD
Pimozide—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0313	0.0391	CbGbCtD
Pimozide—CYP3A4—Betamethasone—ankylosing spondylitis	0.0268	0.0335	CbGbCtD
Pimozide—CYP3A4—Prednisolone—ankylosing spondylitis	0.0265	0.0331	CbGbCtD
Pimozide—ABCB1—Dexamethasone—ankylosing spondylitis	0.0261	0.0326	CbGbCtD
Pimozide—CYP3A4—Prednisone—ankylosing spondylitis	0.025	0.0312	CbGbCtD
Pimozide—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0246	0.0307	CbGbCtD
Pimozide—ABCB1—Methotrexate—ankylosing spondylitis	0.0209	0.0262	CbGbCtD
Pimozide—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0156	0.0195	CbGbCtD
Pimozide—Schizophrenia—Methylprednisolone—ankylosing spondylitis	0.00915	0.063	CcSEcCtD
Pimozide—Schizophrenia—Betamethasone—ankylosing spondylitis	0.00832	0.0573	CcSEcCtD
Pimozide—Schizophrenia—Dexamethasone—ankylosing spondylitis	0.00832	0.0573	CcSEcCtD
Pimozide—Schizophrenia—Prednisone—ankylosing spondylitis	0.00725	0.0499	CcSEcCtD
Pimozide—Electroencephalogram abnormal—Prednisone—ankylosing spondylitis	0.00489	0.0336	CcSEcCtD
Pimozide—Abnormal behaviour—Methylprednisolone—ankylosing spondylitis	0.00333	0.0229	CcSEcCtD
Pimozide—Loss of libido—Methotrexate—ankylosing spondylitis	0.00178	0.0122	CcSEcCtD
Pimozide—Nuchal rigidity—Methotrexate—ankylosing spondylitis	0.00158	0.0109	CcSEcCtD
Pimozide—Amenorrhoea—Methylprednisolone—ankylosing spondylitis	0.00141	0.0097	CcSEcCtD
Pimozide—Cataract—Triamcinolone—ankylosing spondylitis	0.0013	0.00898	CcSEcCtD
Pimozide—Amenorrhoea—Dexamethasone—ankylosing spondylitis	0.00128	0.00883	CcSEcCtD
Pimozide—Amenorrhoea—Betamethasone—ankylosing spondylitis	0.00128	0.00883	CcSEcCtD
Pimozide—Endocrine disorder—Prednisone—ankylosing spondylitis	0.00118	0.00815	CcSEcCtD
Pimozide—Cataract—Dexamethasone—ankylosing spondylitis	0.00118	0.00815	CcSEcCtD
Pimozide—Cataract—Betamethasone—ankylosing spondylitis	0.00118	0.00815	CcSEcCtD
Pimozide—Amenorrhoea—Prednisone—ankylosing spondylitis	0.00112	0.00769	CcSEcCtD
Pimozide—Increased appetite—Prednisolone—ankylosing spondylitis	0.00104	0.00718	CcSEcCtD
Pimozide—Visual disturbance—Prednisolone—ankylosing spondylitis	0.00103	0.00712	CcSEcCtD
Pimozide—Cataract—Prednisone—ankylosing spondylitis	0.00103	0.00709	CcSEcCtD
Pimozide—Increased appetite—Triamcinolone—ankylosing spondylitis	0.000959	0.0066	CcSEcCtD
Pimozide—Increased appetite—Methylprednisolone—ankylosing spondylitis	0.000957	0.00659	CcSEcCtD
Pimozide—Speech disorder—Methotrexate—ankylosing spondylitis	0.000953	0.00656	CcSEcCtD
Pimozide—Increased appetite—Betamethasone—ankylosing spondylitis	0.00087	0.00599	CcSEcCtD
Pimozide—Increased appetite—Dexamethasone—ankylosing spondylitis	0.00087	0.00599	CcSEcCtD
Pimozide—Visual disturbance—Dexamethasone—ankylosing spondylitis	0.000863	0.00594	CcSEcCtD
Pimozide—Visual disturbance—Betamethasone—ankylosing spondylitis	0.000863	0.00594	CcSEcCtD
Pimozide—Hyperkinesia—Prednisone—ankylosing spondylitis	0.000856	0.00589	CcSEcCtD
Pimozide—Breast disorder—Methylprednisolone—ankylosing spondylitis	0.000813	0.00559	CcSEcCtD
Pimozide—Weight increased—Prednisolone—ankylosing spondylitis	0.000771	0.00531	CcSEcCtD
Pimozide—Aplastic anaemia—Methotrexate—ankylosing spondylitis	0.00077	0.0053	CcSEcCtD
Pimozide—Increased appetite—Prednisone—ankylosing spondylitis	0.000758	0.00522	CcSEcCtD
Pimozide—Gynaecomastia—Methotrexate—ankylosing spondylitis	0.000734	0.00505	CcSEcCtD
Pimozide—Weight increased—Triamcinolone—ankylosing spondylitis	0.000709	0.00488	CcSEcCtD
Pimozide—Weight increased—Methylprednisolone—ankylosing spondylitis	0.000707	0.00487	CcSEcCtD
Pimozide—Sweating—Methylprednisolone—ankylosing spondylitis	0.000664	0.00457	CcSEcCtD
Pimozide—Visual impairment—Prednisolone—ankylosing spondylitis	0.000653	0.0045	CcSEcCtD
Pimozide—Weight increased—Dexamethasone—ankylosing spondylitis	0.000643	0.00443	CcSEcCtD
Pimozide—Weight increased—Betamethasone—ankylosing spondylitis	0.000643	0.00443	CcSEcCtD
Pimozide—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000639	0.0044	CcSEcCtD
Pimozide—Weight decreased—Betamethasone—ankylosing spondylitis	0.000639	0.0044	CcSEcCtD
Pimozide—Visual disturbance—Methotrexate—ankylosing spondylitis	0.000628	0.00432	CcSEcCtD
Pimozide—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000611	0.00421	CcSEcCtD
Pimozide—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.0006	0.00413	CcSEcCtD
Pimozide—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000581	0.004	CcSEcCtD
Pimozide—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000577	0.00397	CcSEcCtD
Pimozide—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.000567	0.0039	CcSEcCtD
Pimozide—Weight increased—Prednisone—ankylosing spondylitis	0.00056	0.00386	CcSEcCtD
Pimozide—Weight decreased—Prednisone—ankylosing spondylitis	0.000557	0.00383	CcSEcCtD
Pimozide—Vision blurred—Prednisolone—ankylosing spondylitis	0.000556	0.00383	CcSEcCtD
Pimozide—Depression—Prednisone—ankylosing spondylitis	0.000547	0.00377	CcSEcCtD
Pimozide—Visual impairment—Betamethasone—ankylosing spondylitis	0.000545	0.00375	CcSEcCtD
Pimozide—Visual impairment—Dexamethasone—ankylosing spondylitis	0.000545	0.00375	CcSEcCtD
Pimozide—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000545	0.00375	CcSEcCtD
Pimozide—Breast disorder—Methotrexate—ankylosing spondylitis	0.000538	0.0037	CcSEcCtD
Pimozide—Syncope—Prednisolone—ankylosing spondylitis	0.000529	0.00364	CcSEcCtD
Pimozide—Eye disorder—Betamethasone—ankylosing spondylitis	0.000529	0.00364	CcSEcCtD
Pimozide—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000529	0.00364	CcSEcCtD
Pimozide—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000519	0.00357	CcSEcCtD
Pimozide—Convulsion—Prednisolone—ankylosing spondylitis	0.000511	0.00352	CcSEcCtD
Pimozide—Hypertension—Prednisolone—ankylosing spondylitis	0.00051	0.00351	CcSEcCtD
Pimozide—Eosinophilia—Methotrexate—ankylosing spondylitis	0.000509	0.00351	CcSEcCtD
Pimozide—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.000493	0.00339	CcSEcCtD
Pimozide—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000489	0.00336	CcSEcCtD
Pimozide—Syncope—Triamcinolone—ankylosing spondylitis	0.000487	0.00335	CcSEcCtD
Pimozide—Syncope—Methylprednisolone—ankylosing spondylitis	0.000486	0.00334	CcSEcCtD
Pimozide—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000484	0.00333	CcSEcCtD
Pimozide—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000477	0.00328	CcSEcCtD
Pimozide—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000476	0.00328	CcSEcCtD
Pimozide—Shock—Prednisolone—ankylosing spondylitis	0.000474	0.00326	CcSEcCtD
Pimozide—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.000474	0.00326	CcSEcCtD
Pimozide—Convulsion—Triamcinolone—ankylosing spondylitis	0.00047	0.00324	CcSEcCtD
Pimozide—Tachycardia—Prednisolone—ankylosing spondylitis	0.00047	0.00324	CcSEcCtD
Pimozide—Convulsion—Methylprednisolone—ankylosing spondylitis	0.000469	0.00323	CcSEcCtD
Pimozide—Hypertension—Triamcinolone—ankylosing spondylitis	0.000469	0.00323	CcSEcCtD
Pimozide—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000468	0.00322	CcSEcCtD
Pimozide—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000466	0.00321	CcSEcCtD
Pimozide—Myalgia—Triamcinolone—ankylosing spondylitis	0.000462	0.00318	CcSEcCtD
Pimozide—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000461	0.00317	CcSEcCtD
Pimozide—Eye disorder—Prednisone—ankylosing spondylitis	0.00046	0.00317	CcSEcCtD
Pimozide—Drowsiness—Methotrexate—ankylosing spondylitis	0.000459	0.00316	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000458	0.00315	CcSEcCtD
Pimozide—Depression—Methotrexate—ankylosing spondylitis	0.000457	0.00315	CcSEcCtD
Pimozide—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000452	0.00311	CcSEcCtD
Pimozide—Syncope—Dexamethasone—ankylosing spondylitis	0.000442	0.00304	CcSEcCtD
Pimozide—Syncope—Betamethasone—ankylosing spondylitis	0.000442	0.00304	CcSEcCtD
Pimozide—Sweating—Methotrexate—ankylosing spondylitis	0.00044	0.00303	CcSEcCtD
Pimozide—Shock—Triamcinolone—ankylosing spondylitis	0.000436	0.003	CcSEcCtD
Pimozide—Insomnia—Prednisolone—ankylosing spondylitis	0.000436	0.003	CcSEcCtD
Pimozide—Shock—Methylprednisolone—ankylosing spondylitis	0.000435	0.00299	CcSEcCtD
Pimozide—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000433	0.00298	CcSEcCtD
Pimozide—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000433	0.00298	CcSEcCtD
Pimozide—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000433	0.00298	CcSEcCtD
Pimozide—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000432	0.00298	CcSEcCtD
Pimozide—Mental disorder—Prednisone—ankylosing spondylitis	0.000432	0.00297	CcSEcCtD
Pimozide—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000431	0.00297	CcSEcCtD
Pimozide—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000429	0.00295	CcSEcCtD
Pimozide—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000428	0.00295	CcSEcCtD
Pimozide—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000428	0.00295	CcSEcCtD
Pimozide—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000427	0.00294	CcSEcCtD
Pimozide—Convulsion—Dexamethasone—ankylosing spondylitis	0.000427	0.00294	CcSEcCtD
Pimozide—Convulsion—Betamethasone—ankylosing spondylitis	0.000427	0.00294	CcSEcCtD
Pimozide—Hypertension—Betamethasone—ankylosing spondylitis	0.000425	0.00293	CcSEcCtD
Pimozide—Hypertension—Dexamethasone—ankylosing spondylitis	0.000425	0.00293	CcSEcCtD
Pimozide—Myalgia—Dexamethasone—ankylosing spondylitis	0.000419	0.00289	CcSEcCtD
Pimozide—Myalgia—Betamethasone—ankylosing spondylitis	0.000419	0.00289	CcSEcCtD
Pimozide—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000413	0.00284	CcSEcCtD
Pimozide—Vision blurred—Prednisone—ankylosing spondylitis	0.000404	0.00278	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000404	0.00278	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000403	0.00277	CcSEcCtD
Pimozide—Insomnia—Triamcinolone—ankylosing spondylitis	0.000401	0.00276	CcSEcCtD
Pimozide—Insomnia—Methylprednisolone—ankylosing spondylitis	0.0004	0.00275	CcSEcCtD
Pimozide—Visual impairment—Methotrexate—ankylosing spondylitis	0.000397	0.00273	CcSEcCtD
Pimozide—Anaemia—Prednisone—ankylosing spondylitis	0.000396	0.00273	CcSEcCtD
Pimozide—Shock—Dexamethasone—ankylosing spondylitis	0.000395	0.00272	CcSEcCtD
Pimozide—Shock—Betamethasone—ankylosing spondylitis	0.000395	0.00272	CcSEcCtD
Pimozide—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000394	0.00271	CcSEcCtD
Pimozide—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000394	0.00271	CcSEcCtD
Pimozide—Agitation—Prednisone—ankylosing spondylitis	0.000394	0.00271	CcSEcCtD
Pimozide—Tachycardia—Betamethasone—ankylosing spondylitis	0.000392	0.0027	CcSEcCtD
Pimozide—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000392	0.0027	CcSEcCtD
Pimozide—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000389	0.00267	CcSEcCtD
Pimozide—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000389	0.00267	CcSEcCtD
Pimozide—Eye disorder—Methotrexate—ankylosing spondylitis	0.000385	0.00265	CcSEcCtD
Pimozide—Syncope—Prednisone—ankylosing spondylitis	0.000385	0.00265	CcSEcCtD
Pimozide—Anorexia—Betamethasone—ankylosing spondylitis	0.000383	0.00264	CcSEcCtD
Pimozide—Anorexia—Dexamethasone—ankylosing spondylitis	0.000383	0.00264	CcSEcCtD
Pimozide—Urticaria—Prednisolone—ankylosing spondylitis	0.000383	0.00263	CcSEcCtD
Pimozide—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000382	0.00263	CcSEcCtD
Pimozide—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000377	0.00259	CcSEcCtD
Pimozide—Hypotension—Betamethasone—ankylosing spondylitis	0.000376	0.00259	CcSEcCtD
Pimozide—Hypotension—Dexamethasone—ankylosing spondylitis	0.000376	0.00259	CcSEcCtD
Pimozide—Convulsion—Prednisone—ankylosing spondylitis	0.000372	0.00256	CcSEcCtD
Pimozide—Hypertension—Prednisone—ankylosing spondylitis	0.00037	0.00255	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000366	0.00252	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000366	0.00252	CcSEcCtD
Pimozide—Myalgia—Prednisone—ankylosing spondylitis	0.000365	0.00251	CcSEcCtD
Pimozide—Insomnia—Betamethasone—ankylosing spondylitis	0.000364	0.0025	CcSEcCtD
Pimozide—Insomnia—Dexamethasone—ankylosing spondylitis	0.000364	0.0025	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000363	0.0025	CcSEcCtD
Pimozide—Mental disorder—Methotrexate—ankylosing spondylitis	0.000361	0.00248	CcSEcCtD
Pimozide—Urticaria—Triamcinolone—ankylosing spondylitis	0.000352	0.00242	CcSEcCtD
Pimozide—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000351	0.00242	CcSEcCtD
Pimozide—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000349	0.0024	CcSEcCtD
Pimozide—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000349	0.0024	CcSEcCtD
Pimozide—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000347	0.00239	CcSEcCtD
Pimozide—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000347	0.00239	CcSEcCtD
Pimozide—Shock—Prednisone—ankylosing spondylitis	0.000344	0.00237	CcSEcCtD
Pimozide—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000343	0.00236	CcSEcCtD
Pimozide—Tachycardia—Prednisone—ankylosing spondylitis	0.000342	0.00235	CcSEcCtD
Pimozide—Skin disorder—Prednisone—ankylosing spondylitis	0.00034	0.00234	CcSEcCtD
Pimozide—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000338	0.00233	CcSEcCtD
Pimozide—Vision blurred—Methotrexate—ankylosing spondylitis	0.000338	0.00233	CcSEcCtD
Pimozide—Anorexia—Prednisone—ankylosing spondylitis	0.000334	0.0023	CcSEcCtD
Pimozide—Anaemia—Methotrexate—ankylosing spondylitis	0.000331	0.00228	CcSEcCtD
Pimozide—Leukopenia—Methotrexate—ankylosing spondylitis	0.000321	0.00221	CcSEcCtD
Pimozide—Urticaria—Betamethasone—ankylosing spondylitis	0.000319	0.0022	CcSEcCtD
Pimozide—Urticaria—Dexamethasone—ankylosing spondylitis	0.000319	0.0022	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000319	0.0022	CcSEcCtD
Pimozide—Dizziness—Prednisolone—ankylosing spondylitis	0.000319	0.00219	CcSEcCtD
Pimozide—Asthenia—Triamcinolone—ankylosing spondylitis	0.000318	0.00219	CcSEcCtD
Pimozide—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000317	0.00218	CcSEcCtD
Pimozide—Insomnia—Prednisone—ankylosing spondylitis	0.000317	0.00218	CcSEcCtD
Pimozide—Pruritus—Triamcinolone—ankylosing spondylitis	0.000313	0.00216	CcSEcCtD
Pimozide—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000313	0.00215	CcSEcCtD
Pimozide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000312	0.00574	CbGpPWpGaD
Pimozide—Convulsion—Methotrexate—ankylosing spondylitis	0.000311	0.00214	CcSEcCtD
Pimozide—HTR2A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000306	0.00563	CbGpPWpGaD
Pimozide—Myalgia—Methotrexate—ankylosing spondylitis	0.000305	0.0021	CcSEcCtD
Pimozide—Chest pain—Methotrexate—ankylosing spondylitis	0.000305	0.0021	CcSEcCtD
Pimozide—Decreased appetite—Prednisone—ankylosing spondylitis	0.000304	0.00209	CcSEcCtD
Pimozide—Rash—Prednisolone—ankylosing spondylitis	0.000304	0.00209	CcSEcCtD
Pimozide—Dermatitis—Prednisolone—ankylosing spondylitis	0.000303	0.00209	CcSEcCtD
Pimozide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000303	0.00209	CcSEcCtD
Pimozide—CALM3—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000303	0.00557	CbGpPWpGaD
Pimozide—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000302	0.00208	CcSEcCtD
Pimozide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000302	0.00555	CbGpPWpGaD
Pimozide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000302	0.00555	CbGpPWpGaD
Pimozide—Headache—Prednisolone—ankylosing spondylitis	0.000302	0.00208	CcSEcCtD
Pimozide—CHRM2—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000301	0.00553	CbGpPWpGaD
Pimozide—Constipation—Prednisone—ankylosing spondylitis	0.000299	0.00206	CcSEcCtD
Pimozide—CALM2—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000293	0.00539	CbGpPWpGaD
Pimozide—CALM1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000293	0.00539	CbGpPWpGaD
Pimozide—Dizziness—Triamcinolone—ankylosing spondylitis	0.000293	0.00202	CcSEcCtD
Pimozide—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000292	0.00201	CcSEcCtD
Pimozide—Asthenia—Betamethasone—ankylosing spondylitis	0.000288	0.00198	CcSEcCtD
Pimozide—Asthenia—Dexamethasone—ankylosing spondylitis	0.000288	0.00198	CcSEcCtD
Pimozide—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000287	0.00197	CcSEcCtD
Pimozide—Nausea—Prednisolone—ankylosing spondylitis	0.000286	0.00197	CcSEcCtD
Pimozide—Pruritus—Dexamethasone—ankylosing spondylitis	0.000284	0.00196	CcSEcCtD
Pimozide—Pruritus—Betamethasone—ankylosing spondylitis	0.000284	0.00196	CcSEcCtD
Pimozide—Skin disorder—Methotrexate—ankylosing spondylitis	0.000284	0.00196	CcSEcCtD
Pimozide—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000283	0.00195	CcSEcCtD
Pimozide—Vomiting—Triamcinolone—ankylosing spondylitis	0.000282	0.00194	CcSEcCtD
Pimozide—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000281	0.00193	CcSEcCtD
Pimozide—KCNH2—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000281	0.00516	CbGpPWpGaD
Pimozide—Rash—Triamcinolone—ankylosing spondylitis	0.000279	0.00192	CcSEcCtD
Pimozide—KCNH2—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000279	0.00513	CbGpPWpGaD
Pimozide—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000279	0.00192	CcSEcCtD
Pimozide—Anorexia—Methotrexate—ankylosing spondylitis	0.000279	0.00192	CcSEcCtD
Pimozide—Rash—Methylprednisolone—ankylosing spondylitis	0.000279	0.00192	CcSEcCtD
Pimozide—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000278	0.00192	CcSEcCtD
Pimozide—Urticaria—Prednisone—ankylosing spondylitis	0.000278	0.00191	CcSEcCtD
Pimozide—Headache—Triamcinolone—ankylosing spondylitis	0.000278	0.00191	CcSEcCtD
Pimozide—Headache—Methylprednisolone—ankylosing spondylitis	0.000277	0.00191	CcSEcCtD
Pimozide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000276	0.00507	CbGpPWpGaD
Pimozide—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000275	0.00189	CcSEcCtD
Pimozide—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000275	0.00189	CcSEcCtD
Pimozide—Hypotension—Methotrexate—ankylosing spondylitis	0.000273	0.00188	CcSEcCtD
Pimozide—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000267	0.00183	CcSEcCtD
Pimozide—Dizziness—Dexamethasone—ankylosing spondylitis	0.000266	0.00183	CcSEcCtD
Pimozide—Dizziness—Betamethasone—ankylosing spondylitis	0.000266	0.00183	CcSEcCtD
Pimozide—Insomnia—Methotrexate—ankylosing spondylitis	0.000265	0.00182	CcSEcCtD
Pimozide—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000264	0.00485	CbGpPWpGaD
Pimozide—Nausea—Triamcinolone—ankylosing spondylitis	0.000263	0.00181	CcSEcCtD
Pimozide—Nausea—Methylprednisolone—ankylosing spondylitis	0.000263	0.00181	CcSEcCtD
Pimozide—Somnolence—Methotrexate—ankylosing spondylitis	0.00026	0.00179	CcSEcCtD
Pimozide—Vomiting—Betamethasone—ankylosing spondylitis	0.000256	0.00176	CcSEcCtD
Pimozide—Vomiting—Dexamethasone—ankylosing spondylitis	0.000256	0.00176	CcSEcCtD
Pimozide—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000254	0.00175	CcSEcCtD
Pimozide—Rash—Dexamethasone—ankylosing spondylitis	0.000253	0.00174	CcSEcCtD
Pimozide—Rash—Betamethasone—ankylosing spondylitis	0.000253	0.00174	CcSEcCtD
Pimozide—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000253	0.00174	CcSEcCtD
Pimozide—Dermatitis—Betamethasone—ankylosing spondylitis	0.000253	0.00174	CcSEcCtD
Pimozide—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000253	0.00174	CcSEcCtD
Pimozide—Headache—Betamethasone—ankylosing spondylitis	0.000252	0.00173	CcSEcCtD
Pimozide—Headache—Dexamethasone—ankylosing spondylitis	0.000252	0.00173	CcSEcCtD
Pimozide—Asthenia—Prednisone—ankylosing spondylitis	0.000251	0.00173	CcSEcCtD
Pimozide—Pruritus—Prednisone—ankylosing spondylitis	0.000248	0.0017	CcSEcCtD
Pimozide—HTR1A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000245	0.0045	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000241	0.00444	CbGpPWpGaD
Pimozide—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00024	0.00441	CbGpPWpGaD
Pimozide—Diarrhoea—Prednisone—ankylosing spondylitis	0.00024	0.00165	CcSEcCtD
Pimozide—Nausea—Dexamethasone—ankylosing spondylitis	0.000239	0.00164	CcSEcCtD
Pimozide—Nausea—Betamethasone—ankylosing spondylitis	0.000239	0.00164	CcSEcCtD
Pimozide—HTR6—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000236	0.00434	CbGpPWpGaD
Pimozide—Urticaria—Methotrexate—ankylosing spondylitis	0.000232	0.0016	CcSEcCtD
Pimozide—Dizziness—Prednisone—ankylosing spondylitis	0.000231	0.00159	CcSEcCtD
Pimozide—CALM3—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000229	0.00421	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000224	0.00412	CbGpPWpGaD
Pimozide—Vomiting—Prednisone—ankylosing spondylitis	0.000223	0.00153	CcSEcCtD
Pimozide—CALM2—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000222	0.00407	CbGpPWpGaD
Pimozide—CALM1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000222	0.00407	CbGpPWpGaD
Pimozide—Rash—Prednisone—ankylosing spondylitis	0.000221	0.00152	CcSEcCtD
Pimozide—Dermatitis—Prednisone—ankylosing spondylitis	0.000221	0.00152	CcSEcCtD
Pimozide—CALM3—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.00022	0.00405	CbGpPWpGaD
Pimozide—Headache—Prednisone—ankylosing spondylitis	0.000219	0.00151	CcSEcCtD
Pimozide—CALM1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000213	0.00392	CbGpPWpGaD
Pimozide—CALM2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000213	0.00392	CbGpPWpGaD
Pimozide—HTR2A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000211	0.00389	CbGpPWpGaD
Pimozide—Asthenia—Methotrexate—ankylosing spondylitis	0.00021	0.00144	CcSEcCtD
Pimozide—Nausea—Prednisone—ankylosing spondylitis	0.000208	0.00143	CcSEcCtD
Pimozide—CHRM2—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000208	0.00382	CbGpPWpGaD
Pimozide—Pruritus—Methotrexate—ankylosing spondylitis	0.000207	0.00142	CcSEcCtD
Pimozide—CALM3—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000207	0.0038	CbGpPWpGaD
Pimozide—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000205	0.00378	CbGpPWpGaD
Pimozide—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000203	0.00373	CbGpPWpGaD
Pimozide—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000202	0.00372	CbGpPWpGaD
Pimozide—DRD3—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000201	0.00369	CbGpPWpGaD
Pimozide—Diarrhoea—Methotrexate—ankylosing spondylitis	0.0002	0.00138	CcSEcCtD
Pimozide—CALM1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.0002	0.00367	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.0002	0.00367	CbGpPWpGaD
Pimozide—Dizziness—Methotrexate—ankylosing spondylitis	0.000193	0.00133	CcSEcCtD
Pimozide—Vomiting—Methotrexate—ankylosing spondylitis	0.000186	0.00128	CcSEcCtD
Pimozide—Rash—Methotrexate—ankylosing spondylitis	0.000184	0.00127	CcSEcCtD
Pimozide—Dermatitis—Methotrexate—ankylosing spondylitis	0.000184	0.00127	CcSEcCtD
Pimozide—Headache—Methotrexate—ankylosing spondylitis	0.000183	0.00126	CcSEcCtD
Pimozide—CALM3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000183	0.00336	CbGpPWpGaD
Pimozide—CALM3—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000182	0.00335	CbGpPWpGaD
Pimozide—CALM2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000177	0.00325	CbGpPWpGaD
Pimozide—CALM1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000177	0.00325	CbGpPWpGaD
Pimozide—CALM1—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000176	0.00324	CbGpPWpGaD
Pimozide—CALM2—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000176	0.00324	CbGpPWpGaD
Pimozide—HTR1A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000176	0.00324	CbGpPWpGaD
Pimozide—HTR1A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000175	0.00322	CbGpPWpGaD
Pimozide—HTR1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000175	0.00322	CbGpPWpGaD
Pimozide—Nausea—Methotrexate—ankylosing spondylitis	0.000174	0.0012	CcSEcCtD
Pimozide—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000174	0.00319	CbGpPWpGaD
Pimozide—DRD3—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000172	0.00316	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000165	0.00303	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000164	0.00302	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000164	0.00302	CbGpPWpGaD
Pimozide—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000157	0.00288	CbGpPWpGaD
Pimozide—OPRK1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000156	0.00288	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000156	0.00287	CbGpPWpGaD
Pimozide—HTR6—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000154	0.00283	CbGpPWpGaD
Pimozide—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000154	0.00282	CbGpPWpGaD
Pimozide—HTR2A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000152	0.0028	CbGpPWpGaD
Pimozide—HTR2A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000151	0.00278	CbGpPWpGaD
Pimozide—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000151	0.00278	CbGpPWpGaD
Pimozide—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000151	0.00277	CbGpPWpGaD
Pimozide—HTR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00015	0.00275	CbGpPWpGaD
Pimozide—CHRM2—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000149	0.00275	CbGpPWpGaD
Pimozide—CHRM2—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000149	0.00273	CbGpPWpGaD
Pimozide—CHRM2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000148	0.00273	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000145	0.00266	CbGpPWpGaD
Pimozide—OPRM1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000132	0.00243	CbGpPWpGaD
Pimozide—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000132	0.00242	CbGpPWpGaD
Pimozide—DRD3—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000131	0.00241	CbGpPWpGaD
Pimozide—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000129	0.00238	CbGpPWpGaD
Pimozide—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000129	0.00237	CbGpPWpGaD
Pimozide—CALM3—B Cell Activation—CD79A—ankylosing spondylitis	0.000129	0.00237	CbGpPWpGaD
Pimozide—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000127	0.00234	CbGpPWpGaD
Pimozide—CALM3—Immune System—KIR3DL1—ankylosing spondylitis	0.000125	0.0023	CbGpPWpGaD
Pimozide—CALM2—B Cell Activation—CD79A—ankylosing spondylitis	0.000125	0.00229	CbGpPWpGaD
Pimozide—CALM1—B Cell Activation—CD79A—ankylosing spondylitis	0.000125	0.00229	CbGpPWpGaD
Pimozide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000125	0.00229	CbGpPWpGaD
Pimozide—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000124	0.00228	CbGpPWpGaD
Pimozide—CALM2—Immune System—KIR3DL1—ankylosing spondylitis	0.000121	0.00223	CbGpPWpGaD
Pimozide—CALM1—Immune System—KIR3DL1—ankylosing spondylitis	0.000121	0.00223	CbGpPWpGaD
Pimozide—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000119	0.00218	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000119	0.00218	CbGpPWpGaD
Pimozide—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000115	0.00211	CbGpPWpGaD
Pimozide—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000115	0.00211	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000115	0.00211	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000115	0.00211	CbGpPWpGaD
Pimozide—HTR1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000114	0.0021	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—CARD9—ankylosing spondylitis	0.000113	0.00208	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—CARD9—ankylosing spondylitis	0.000109	0.00201	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—CARD9—ankylosing spondylitis	0.000109	0.00201	CbGpPWpGaD
Pimozide—CALM3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000108	0.00198	CbGpPWpGaD
Pimozide—CALM2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000106	0.00196	CbGpPWpGaD
Pimozide—CALM1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000106	0.00196	CbGpPWpGaD
Pimozide—KCNH2—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000106	0.00195	CbGpPWpGaD
Pimozide—CALM2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000104	0.00192	CbGpPWpGaD
Pimozide—CALM1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000104	0.00192	CbGpPWpGaD
Pimozide—DRD2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.0001	0.00184	CbGpPWpGaD
Pimozide—HTR2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.86e-05	0.00181	CbGpPWpGaD
Pimozide—HRH1—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.84e-05	0.00181	CbGpPWpGaD
Pimozide—CHRM2—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.68e-05	0.00178	CbGpPWpGaD
Pimozide—CALM3—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	9.51e-05	0.00175	CbGpPWpGaD
Pimozide—CALM1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	9.2e-05	0.00169	CbGpPWpGaD
Pimozide—CALM2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	9.2e-05	0.00169	CbGpPWpGaD
Pimozide—OPRK1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	8.84e-05	0.00163	CbGpPWpGaD
Pimozide—CALM3—Disease—ANTXR2—ankylosing spondylitis	8.77e-05	0.00161	CbGpPWpGaD
Pimozide—HTR6—GPCR downstream signaling—PTGER4—ankylosing spondylitis	8.71e-05	0.0016	CbGpPWpGaD
Pimozide—CALM2—Disease—ANTXR2—ankylosing spondylitis	8.48e-05	0.00156	CbGpPWpGaD
Pimozide—CALM1—Disease—ANTXR2—ankylosing spondylitis	8.48e-05	0.00156	CbGpPWpGaD
Pimozide—CALM3—Alzheimers Disease—TNF—ankylosing spondylitis	8.24e-05	0.00151	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—PTGER4—ankylosing spondylitis	8.03e-05	0.00148	CbGpPWpGaD
Pimozide—CALM2—Alzheimers Disease—TNF—ankylosing spondylitis	7.97e-05	0.00146	CbGpPWpGaD
Pimozide—CALM1—Alzheimers Disease—TNF—ankylosing spondylitis	7.97e-05	0.00146	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.91e-05	0.00145	CbGpPWpGaD
Pimozide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	7.68e-05	0.00141	CbGpPWpGaD
Pimozide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	7.68e-05	0.00141	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL1R2—ankylosing spondylitis	7.59e-05	0.0014	CbGpPWpGaD
Pimozide—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	7.59e-05	0.00139	CbGpPWpGaD
Pimozide—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	7.59e-05	0.00139	CbGpPWpGaD
Pimozide—OPRM1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.47e-05	0.00137	CbGpPWpGaD
Pimozide—DRD3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.4e-05	0.00136	CbGpPWpGaD
Pimozide—CACNA1G—Developmental Biology—TNF—ankylosing spondylitis	7.36e-05	0.00135	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL1R2—ankylosing spondylitis	7.34e-05	0.00135	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL1R2—ankylosing spondylitis	7.34e-05	0.00135	CbGpPWpGaD
Pimozide—CALM3—Immune System—ERAP1—ankylosing spondylitis	7.2e-05	0.00132	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—HLA-C—ankylosing spondylitis	7.1e-05	0.0013	CbGpPWpGaD
Pimozide—CALM2—Immune System—ERAP1—ankylosing spondylitis	6.96e-05	0.00128	CbGpPWpGaD
Pimozide—CALM1—Immune System—ERAP1—ankylosing spondylitis	6.96e-05	0.00128	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—HLA-C—ankylosing spondylitis	6.86e-05	0.00126	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—HLA-C—ankylosing spondylitis	6.86e-05	0.00126	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—HLA-C—ankylosing spondylitis	6.81e-05	0.00125	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.79e-05	0.00125	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.72e-05	0.00124	CbGpPWpGaD
Pimozide—HTR1A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	6.67e-05	0.00123	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—HLA-C—ankylosing spondylitis	6.59e-05	0.00121	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—HLA-C—ankylosing spondylitis	6.59e-05	0.00121	CbGpPWpGaD
Pimozide—CALM3—Immune System—CARD9—ankylosing spondylitis	6.58e-05	0.00121	CbGpPWpGaD
Pimozide—HTR1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	6.45e-05	0.00119	CbGpPWpGaD
Pimozide—CALM1—Immune System—CARD9—ankylosing spondylitis	6.37e-05	0.00117	CbGpPWpGaD
Pimozide—CALM2—Immune System—CARD9—ankylosing spondylitis	6.37e-05	0.00117	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	6.24e-05	0.00115	CbGpPWpGaD
Pimozide—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	6.01e-05	0.0011	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.86e-05	0.00108	CbGpPWpGaD
Pimozide—HTR2A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	5.76e-05	0.00106	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—MMP3—ankylosing spondylitis	5.72e-05	0.00105	CbGpPWpGaD
Pimozide—DRD2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.66e-05	0.00104	CbGpPWpGaD
Pimozide—CHRM2—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	5.65e-05	0.00104	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—MMP3—ankylosing spondylitis	5.63e-05	0.00104	CbGpPWpGaD
Pimozide—HTR2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.57e-05	0.00102	CbGpPWpGaD
Pimozide—HRH1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.56e-05	0.00102	CbGpPWpGaD
Pimozide—CHRM2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.47e-05	0.00101	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—CD79A—ankylosing spondylitis	5.2e-05	0.000955	CbGpPWpGaD
Pimozide—CALM3—Disease—B3GNT2—ankylosing spondylitis	5.17e-05	0.00095	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.14e-05	0.000945	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.06e-05	0.00093	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.05e-05	0.000928	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—CD79A—ankylosing spondylitis	5.03e-05	0.000924	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—CD79A—ankylosing spondylitis	5.03e-05	0.000924	CbGpPWpGaD
Pimozide—CALM1—Disease—B3GNT2—ankylosing spondylitis	5e-05	0.000919	CbGpPWpGaD
Pimozide—CALM2—Disease—B3GNT2—ankylosing spondylitis	5e-05	0.000919	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.97e-05	0.000913	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—MMP3—ankylosing spondylitis	4.83e-05	0.000888	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—MMP3—ankylosing spondylitis	4.79e-05	0.00088	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.74e-05	0.000872	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—PTGER4—ankylosing spondylitis	4.67e-05	0.000859	CbGpPWpGaD
Pimozide—CYP2E1—Metabolism—B3GNT2—ankylosing spondylitis	4.35e-05	0.0008	CbGpPWpGaD
Pimozide—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	4.35e-05	0.000799	CbGpPWpGaD
Pimozide—CALM3—Metabolism—B3GNT2—ankylosing spondylitis	4.33e-05	0.000795	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—CD40LG—ankylosing spondylitis	4.24e-05	0.000779	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.2e-05	0.000772	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—HLA-B—ankylosing spondylitis	4.2e-05	0.000771	CbGpPWpGaD
Pimozide—CALM2—Metabolism—B3GNT2—ankylosing spondylitis	4.19e-05	0.000769	CbGpPWpGaD
Pimozide—CALM1—Metabolism—B3GNT2—ankylosing spondylitis	4.19e-05	0.000769	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—MMP3—ankylosing spondylitis	4.17e-05	0.000767	CbGpPWpGaD
Pimozide—CALM3—Immune System—HLA-C—ankylosing spondylitis	4.13e-05	0.00076	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—CD40LG—ankylosing spondylitis	4.1e-05	0.000753	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—CD40LG—ankylosing spondylitis	4.1e-05	0.000753	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.06e-05	0.000747	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.06e-05	0.000747	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—HLA-B—ankylosing spondylitis	4.06e-05	0.000746	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—HLA-B—ankylosing spondylitis	4.06e-05	0.000746	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—HLA-B—ankylosing spondylitis	4.03e-05	0.000741	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—PTGER4—ankylosing spondylitis	4.01e-05	0.000737	CbGpPWpGaD
Pimozide—CALM1—Immune System—HLA-C—ankylosing spondylitis	4e-05	0.000735	CbGpPWpGaD
Pimozide—CALM2—Immune System—HLA-C—ankylosing spondylitis	4e-05	0.000735	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—PTGER4—ankylosing spondylitis	3.97e-05	0.00073	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—HLA-B—ankylosing spondylitis	3.9e-05	0.000716	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—HLA-B—ankylosing spondylitis	3.9e-05	0.000716	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—HLA-A—ankylosing spondylitis	3.73e-05	0.000686	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—CRP—ankylosing spondylitis	3.71e-05	0.000682	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—MMP3—ankylosing spondylitis	3.66e-05	0.000673	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—HLA-A—ankylosing spondylitis	3.61e-05	0.000664	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—HLA-A—ankylosing spondylitis	3.61e-05	0.000664	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—MMP3—ankylosing spondylitis	3.6e-05	0.000662	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—MMP3—ankylosing spondylitis	3.6e-05	0.000661	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL1RN—ankylosing spondylitis	3.59e-05	0.00066	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—CRP—ankylosing spondylitis	3.59e-05	0.000659	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—CRP—ankylosing spondylitis	3.59e-05	0.000659	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—TLR4—ankylosing spondylitis	3.56e-05	0.000654	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—MMP3—ankylosing spondylitis	3.54e-05	0.00065	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL1RN—ankylosing spondylitis	3.47e-05	0.000638	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL1RN—ankylosing spondylitis	3.47e-05	0.000638	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—PTGER4—ankylosing spondylitis	3.46e-05	0.000636	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—TLR4—ankylosing spondylitis	3.44e-05	0.000632	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—TLR4—ankylosing spondylitis	3.44e-05	0.000632	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—MMP3—ankylosing spondylitis	3.38e-05	0.000621	CbGpPWpGaD
Pimozide—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	3.36e-05	0.000618	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—MMP3—ankylosing spondylitis	3.33e-05	0.000612	CbGpPWpGaD
Pimozide—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.28e-05	0.000603	CbGpPWpGaD
Pimozide—CALM3—Immune System—CD79A—ankylosing spondylitis	3.15e-05	0.000579	CbGpPWpGaD
Pimozide—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.09e-05	0.000568	CbGpPWpGaD
Pimozide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.08e-05	0.000566	CbGpPWpGaD
Pimozide—CALM1—Immune System—CD79A—ankylosing spondylitis	3.05e-05	0.00056	CbGpPWpGaD
Pimozide—CALM2—Immune System—CD79A—ankylosing spondylitis	3.05e-05	0.00056	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—PTGER4—ankylosing spondylitis	3.04e-05	0.000558	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—MMP3—ankylosing spondylitis	2.99e-05	0.00055	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—PTGER4—ankylosing spondylitis	2.99e-05	0.000549	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—PTGER4—ankylosing spondylitis	2.98e-05	0.000548	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—PTGER4—ankylosing spondylitis	2.94e-05	0.000539	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—MMP3—ankylosing spondylitis	2.89e-05	0.000532	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—MMP3—ankylosing spondylitis	2.89e-05	0.000532	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—MMP3—ankylosing spondylitis	2.85e-05	0.000525	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—MMP3—ankylosing spondylitis	2.83e-05	0.00052	CbGpPWpGaD
Pimozide—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	2.62e-05	0.000481	CbGpPWpGaD
Pimozide—CALM3—Immune System—IL1A—ankylosing spondylitis	2.58e-05	0.000475	CbGpPWpGaD
Pimozide—CALM3—Immune System—CD40LG—ankylosing spondylitis	2.57e-05	0.000472	CbGpPWpGaD
Pimozide—CALM1—Immune System—IL1A—ankylosing spondylitis	2.5e-05	0.000459	CbGpPWpGaD
Pimozide—CALM2—Immune System—IL1A—ankylosing spondylitis	2.5e-05	0.000459	CbGpPWpGaD
Pimozide—CALM2—Immune System—CD40LG—ankylosing spondylitis	2.49e-05	0.000457	CbGpPWpGaD
Pimozide—CALM1—Immune System—CD40LG—ankylosing spondylitis	2.49e-05	0.000457	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—PTGER4—ankylosing spondylitis	2.48e-05	0.000456	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—MMP3—ankylosing spondylitis	2.46e-05	0.000453	CbGpPWpGaD
Pimozide—CALM3—Immune System—HLA-B—ankylosing spondylitis	2.44e-05	0.000449	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—PTGER4—ankylosing spondylitis	2.4e-05	0.000441	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—PTGER4—ankylosing spondylitis	2.4e-05	0.000441	CbGpPWpGaD
Pimozide—CALM2—Immune System—HLA-B—ankylosing spondylitis	2.36e-05	0.000435	CbGpPWpGaD
Pimozide—CALM1—Immune System—HLA-B—ankylosing spondylitis	2.36e-05	0.000435	CbGpPWpGaD
Pimozide—CALM3—Immune System—HLA-A—ankylosing spondylitis	2.26e-05	0.000416	CbGpPWpGaD
Pimozide—CALM2—Immune System—HLA-A—ankylosing spondylitis	2.19e-05	0.000403	CbGpPWpGaD
Pimozide—CALM1—Immune System—HLA-A—ankylosing spondylitis	2.19e-05	0.000403	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—MMP3—ankylosing spondylitis	2.16e-05	0.000398	CbGpPWpGaD
Pimozide—CALM3—Immune System—CRP—ankylosing spondylitis	2.16e-05	0.000397	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—MMP3—ankylosing spondylitis	2.13e-05	0.000391	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—MMP3—ankylosing spondylitis	2.12e-05	0.00039	CbGpPWpGaD
Pimozide—CALM3—Disease—HLA-A—ankylosing spondylitis	2.09e-05	0.000384	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—MMP3—ankylosing spondylitis	2.09e-05	0.000384	CbGpPWpGaD
Pimozide—CALM2—Immune System—CRP—ankylosing spondylitis	2.09e-05	0.000384	CbGpPWpGaD
Pimozide—CALM1—Immune System—CRP—ankylosing spondylitis	2.09e-05	0.000384	CbGpPWpGaD
Pimozide—CALM3—Immune System—TLR4—ankylosing spondylitis	2.07e-05	0.000381	CbGpPWpGaD
Pimozide—CALM1—Disease—HLA-A—ankylosing spondylitis	2.02e-05	0.000372	CbGpPWpGaD
Pimozide—CALM2—Disease—HLA-A—ankylosing spondylitis	2.02e-05	0.000372	CbGpPWpGaD
Pimozide—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.02e-05	0.000371	CbGpPWpGaD
Pimozide—CALM2—Immune System—TLR4—ankylosing spondylitis	2e-05	0.000368	CbGpPWpGaD
Pimozide—CALM1—Immune System—TLR4—ankylosing spondylitis	2e-05	0.000368	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—MMP3—ankylosing spondylitis	1.77e-05	0.000325	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—MMP3—ankylosing spondylitis	1.71e-05	0.000314	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—MMP3—ankylosing spondylitis	1.71e-05	0.000314	CbGpPWpGaD
